Back to Search
ANDREW WAKELING, D.O.
D.O.
Student in an Organized Health Care Education/Training Program
NPI: 1336999424Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
PMID 16912207·Cancer Res·2006
7-preclinical
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.
PMID 16113086·Endocr Relat Cancer·2005
6-review
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
PMID 15613453·Endocr Relat Cancer·2004
4-observational
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).
PMID 15387370·Clin Exp Metastasis·2004
8-other
Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
PMID 15377841·Breast Cancer Res Treat·2004
8-other
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
PMID 15199112·J Natl Cancer Inst·2004
7-preclinical
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.
PMID 15094757·Br J Cancer·2004
6-review
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
PMID 14679152·J Natl Cancer Inst·2003
7-preclinical
Therapeutic potential of tyrosine kinase inhibitors in breast cancer.
PMID 14628436·Cancer Invest·2003
6-review
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
PMID 14531500·Breast Cancer Res Treat·2003
8-other
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
PMID 12960029·Endocrinology·2003
8-other
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
PMID 12586780·Endocrinology·2003
8-other
Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
PMID 12542403·Endocr Relat Cancer·2002
6-review
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
PMID 12384534·Cancer Res·2002
7-preclinical
Epidermal growth factor receptor tyrosine kinase inhibitors.
PMID 12127870·Curr Opin Pharmacol·2002
6-review
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
PMID 12095935·Ann N Y Acad Sci·2002
8-other
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor.
PMID 12011069·J Biol Chem·2002
7-preclinical
Multiple responses to EGF receptor activation and their abrogation by a specific EGF receptor tyrosine kinase inhibitor.
PMID 11992620·Prostate·2002
8-other
Prospects for combining hormonal and nonhormonal growth factor inhibition.
PMID 11916224·Clin Cancer Res·2001
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2500 METROHEALTH DRIVE
CLEVELAND, OH 44109 - Phone
- (216) 778-4486
Quick Facts
- NPI
- 1336999424
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile